[go: up one dir, main page]

MX2018007589A - Ccl20 como indicador de respuesta clinica a antagonistas de il23. - Google Patents

Ccl20 como indicador de respuesta clinica a antagonistas de il23.

Info

Publication number
MX2018007589A
MX2018007589A MX2018007589A MX2018007589A MX2018007589A MX 2018007589 A MX2018007589 A MX 2018007589A MX 2018007589 A MX2018007589 A MX 2018007589A MX 2018007589 A MX2018007589 A MX 2018007589A MX 2018007589 A MX2018007589 A MX 2018007589A
Authority
MX
Mexico
Prior art keywords
ccl20
disease
treatment
therapeutic agent
mediated disease
Prior art date
Application number
MX2018007589A
Other languages
English (en)
Inventor
Rees William
Liang Meina
Higgs Brandon
Wah Lee Yen-
Streicher Katie
Ranade Koustubh
Vainshtein Inna
Li Jing
Morehouse Chris
Faggioni Raffaella
Chen Jingjing
W Iii Georgantas Robert
A Jr Gasser Robert
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2018007589A publication Critical patent/MX2018007589A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención hace referencia al uso de ligando de quimiocina (motivo C-C) 20(CCL20) como un biomarcador para estratificar o identificar poblaciones de pacientes que padecen enfermedades mediadas por interleucina 23 (IL23) (por ejemplo, enfermedad de Crohn) que responden al tratamiento con un antagonista anti-IL23 (lo que incluye, por ejemplo, anticuerpos anti-IL23). Es posible utilizar niveles de CCL20 por encima o por debajo de un umbral predeterminado, por ejemplo, (i) para determinar si se puede seleccionar un paciente con un trastorno o enfermedad mediado por IL23, tal como enfermedad de Crohn, o no para tratamiento con un agente terapéutico, (ii) para determinar si se debería iniciar, interrumpir o modificar el tratamiento con un agente determinado, (iii) para diagnosticar si la enfermedad mediada por IL23 se puede tratar o no con un agente terapéutico específico, o (iv) para predecir el resultado del tratamiento de la enfermedad mediada por IL23 con un agente terapéutico específico. CCL20 se puede utilizar en combinación con otros biomarcadores de la vía de IL23, tales como IL22 y/o lipocalina 2 (LCN2).
MX2018007589A 2015-12-22 2016-12-16 Ccl20 como indicador de respuesta clinica a antagonistas de il23. MX2018007589A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562271156P 2015-12-22 2015-12-22
PCT/US2016/067120 WO2017112536A1 (en) 2015-12-22 2016-12-16 Ccl20 as a predictor of clinical response to il23-antagonists

Publications (1)

Publication Number Publication Date
MX2018007589A true MX2018007589A (es) 2018-11-09

Family

ID=59091179

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007589A MX2018007589A (es) 2015-12-22 2016-12-16 Ccl20 como indicador de respuesta clinica a antagonistas de il23.

Country Status (12)

Country Link
US (2) US11220541B2 (es)
EP (1) EP3393515A4 (es)
JP (2) JP2019508370A (es)
KR (1) KR20180096633A (es)
CN (1) CN108472367A (es)
AU (1) AU2016379157A1 (es)
BR (1) BR112018012626A2 (es)
CA (1) CA3007098A1 (es)
IL (1) IL259704A (es)
MX (1) MX2018007589A (es)
RU (1) RU2018124603A (es)
WO (1) WO2017112536A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN116672446A (zh) 2015-09-17 2023-09-01 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
US10961307B2 (en) * 2018-09-24 2021-03-30 Janssen Biotech, Inc. Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
WO2020198493A2 (en) * 2019-03-26 2020-10-01 Astrazeneca Collaboration Ventures, Llc Patient populations amenable to il23-antagonist therapy
KR20230165746A (ko) 2020-11-30 2023-12-05 민데라 코포레이션 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이
CN113092652B (zh) * 2021-03-19 2022-09-30 浙江工商大学 一种用于评估个体过敏程度的试剂盒
CN114113630B (zh) * 2021-11-24 2023-07-28 中南大学湘雅医院 Serpinb3/b4作为靶点在玫瑰痤疮等炎症性皮肤病治疗药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8318754D0 (en) 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5455160A (en) 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
JP4105768B2 (ja) 1996-11-01 2008-06-25 マグネ・コー・ファージェルホール タンパク質の抽出方法
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CO4810232A1 (es) 1997-07-25 1999-06-30 Schering Corp Citoquinas de mamiferos y sus secuencias codificadoras
JP2007527246A (ja) 2004-03-05 2007-09-27 アーケミックス コーポレイション ヒトｉｌ−１２サイトカインファミリーに対するアプタマーおよび自己免疫疾患の治療剤としてのそれらの使用
AU2005240190C1 (en) 2004-05-06 2012-01-19 Children's Hospital Medical Center NGAL for reduction and amelioration of ischemic and nephrotoxic injuries
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
US7491391B2 (en) 2005-06-30 2009-02-17 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
PT1937721E (pt) 2005-08-25 2010-09-17 Lilly Co Eli Anticorpos anti-il-23
HUE032131T2 (en) 2005-08-31 2017-09-28 Merck Sharp & Dohme Constructed anti-IL-23 antibodies
NZ621483A (en) 2005-12-02 2015-10-30 Genentech Inc Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
CN101389351B (zh) 2005-12-29 2012-10-10 森托科尔公司 人抗il-23抗体、组合物、方法和用途
WO2007098065A2 (en) 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Human sodium channel isoforms
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
CN101663320A (zh) 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
DK2426144T3 (en) 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
KR20100124326A (ko) 2008-03-14 2010-11-26 엑사젠 다이어그노스틱스, 인코포레이티드 염증성 장 질병 및 과민성 장 증후군에 대한 생체마커
AU2009288419B2 (en) 2008-08-27 2015-08-06 Merck Sharp & Dohme Llc Lyophilized formulatons of engineered anti-IL-23p19 antibodies
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
WO2010042903A1 (en) 2008-10-09 2010-04-15 Alfagene Bioscience, Inc Use and identification of biomarkers for gastrointestinal diseases
WO2010062663A1 (en) 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
WO2010129964A1 (en) 2009-05-08 2010-11-11 The Board Of Trustees Of The University Of Illinois Drug targets for prevention of arrhythmia in heart disease
WO2010142534A1 (en) 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
EP2778685B1 (en) 2009-06-25 2017-04-26 Nestec S.A. Methods for diagnosing irritable bowel syndrome
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CA2781654A1 (en) 2009-11-25 2011-06-03 Hua Gong Novel genomic biomarkers for irritable bowel syndrome diagnosis
ES2753216T3 (es) 2010-01-15 2020-04-07 Amgen K A Inc Formulación de anticuerpos anti-IL17RA y regímenes terapéuticos para el tratamiento de la psoriasis
AU2011282476B2 (en) 2010-07-20 2015-08-20 Cephalon Australia Pty Ltd Anti-IL-23 heterodimer specific antibodies
US8541180B1 (en) 2010-10-11 2013-09-24 Genova Diagnostics, Inc. Compositions and methods for assessing gastrointestinal health
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
JP6116485B2 (ja) 2011-01-06 2017-04-19 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 心臓性突然死に関連する方法において使用するためのｓｃｎ５ａスプライスバリアント
EP2710383B1 (en) 2011-05-16 2017-01-11 The University of Newcastle Performance of a biomarker panel for irritable bowel syndrome
NO20110895A1 (no) 2011-06-21 2012-12-24 Magne Fagerhol Kompetitive S100A9 immunoanalyser
NO336551B1 (no) 2011-06-21 2015-09-28 Magne Fagerhol Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve
WO2013132347A2 (en) 2012-03-06 2013-09-12 Calpro As Improved elisa immunoassay for calprotectin
WO2013132338A2 (en) 2012-03-06 2013-09-12 Calpro As Competitive immunoassay for calprotectin
EP2834370B1 (en) 2012-04-03 2019-01-02 The Regents Of The University Of Michigan Biomarker associated with irritable bowel syndrome and crohn's disease

Also Published As

Publication number Publication date
JP2022031643A (ja) 2022-02-22
BR112018012626A2 (pt) 2018-12-04
WO2017112536A1 (en) 2017-06-29
IL259704A (en) 2018-07-31
EP3393515A1 (en) 2018-10-31
CA3007098A1 (en) 2017-06-29
RU2018124603A (ru) 2020-01-24
US11220541B2 (en) 2022-01-11
RU2018124603A3 (es) 2020-04-06
EP3393515A4 (en) 2019-08-14
AU2016379157A1 (en) 2018-06-21
JP2019508370A (ja) 2019-03-28
KR20180096633A (ko) 2018-08-29
CN108472367A (zh) 2018-08-31
US20220144935A1 (en) 2022-05-12
US20200262907A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
MX2018003376A (es) Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
MX2018007589A (es) Ccl20 como indicador de respuesta clinica a antagonistas de il23.
Fielder et al. Short senolytic or senostatic interventions rescue progression of radiation-induced frailty and premature ageing in mice
Onesti et al. Inflammation based regulation of cancer cachexia
WO2017062456A3 (en) Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
ZA201803207B (en) MR-proADM AS MARKER FOR THE EXTRACELLULAR VOLUME STATUS OF A SUBJECT
BR112014011127A2 (pt) métodos para tratar, diagnosticar e monitorar doença de alzheimer
MX362514B (es) Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
Deangelis et al. Diagnosis of multiple sclerosis
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
EA201291040A1 (ru) Использование скорости увеличения желудочков при лечении болезни альцгеймера внутривенным иммуноглобулином
Baranowska-Bik et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis
MX2020006660A (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato.
MX2019006141A (es) Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes.
JP2017508144A5 (es)
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
Dammak Treatment-resistant schizophrenia: prevalence and risk factors
Lee et al. Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia
WO2011073905A8 (en) Novel tumor markers
WO2019053116A8 (en) Method for guidance of fluid therapy based on proadrenomedullin
MA35216B1 (fr) Sondes et amorces pour la detection du gene bcr-abl en reaction duplex
CN104826131B (zh) miR-17-92基因簇在制备治疗精神类疾病药物中的用途
Loughan et al. P18. 05 Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary Data on Clinical Utility within the Brain Tumor Population